Parabilis Medicines, Inc. — Form 8-K
Filed August 25, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 32/100
What the filing says
Parabilis Medicines announced appointment of Craig L. Tendler, M.D., to its Board of Directors on August 25, 2026. Dr. Tendler, with 30+ years oncology drug development experience including two decades as Global Head of Late-Stage Clinical Development and Medical Affairs for Oncology at Johnson & Johnson, will continue his existing role as scientific advisor. No financial terms, equity grants, or compensation details disclosed.
Why this rating
Board appointment adds credible oncology expertise to clinical-stage biotech; routine governance event with no financial impact disclosed or quantified.
See more from August 25, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.